Evidence map›Paper›PMID 40163149›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Therapeutic innovations: targeting ROS production in AML with natural and synthetic compounds.

Mohammed Hashim Mohammed, Raed Fanoukh Aboqader Al-Aouadi, Subasini Uthirapathy, Gaurav Sanghvi, Rekha M M, Resan Shakir Abdulamer, G V Siva Prasad, Mayank Kundlas, Fayzulla Khamraev, Muhammad Ikram Ullah

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammed Hashim MohammedMedical Laboratory Techniques Department, College of Health and Medical Technology, Al-Maarif University, Anbar, Iraq. Muhammad.hashem@uoa.edu.iq.
Raed Fanoukh Aboqader Al-AouadiCollege of Medicine, Al-Ayen Iraqi University, AUIQ, An Nasiriyah, Iraq.ORCID http://orcid.org/0009-0001-2308-7714
Subasini UthirapathyPharmacy Department, Tishk International University, Erbil, Kurdistan Region, Iraq.
Gaurav SanghviDepartment of Microbiology, Faculty of Science, Marwadi University Research Center, Marwadi University, Rajkot, 360003, Gujarat, India.
Rekha M MDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Resan Shakir AbdulamerDepartment of Medical Laboratories Technology, Al-Nisour University College, Nisour Seq. Karkh, Baghdad, Iraq.
G V Siva PrasadDepartment of Chemistry, Raghu Engineering College, Visakhapatnam, Andhra Pradesh, 531162, India.
Mayank KundlasCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.ORCID http://orcid.org/0009-0001-7119-2383
Fayzulla KhamraevUniversity of Mining and Technologies, Navoiy, Uzbekistan.ORCID http://orcid.org/0009-0005-6788-5004
Muhammad Ikram UllahDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, 72388, Sakaka, Aljouf, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reactive oxygen species (ROS) play a dual role in the pathophysiology of acute myeloid leukemia (AML), functioning as both signaling molecules and agents of cellular damage. This review offers an in-depth analysis of ROS production in AML, highlighting their impact on essential cellular pathways that govern cell survival, proliferation, and apoptosis. It explores both natural and synthetic pharmacological agents that modulate ROS generation and enhance oxidative stress, assessing their therapeutic potential and the challenges they present in clinical practice. Additionally, the review identifies ROS-associated prognostic biomarkers that could enhance patient stratification and improve treatment outcomes in AML. Despite the promising potential of ROS-targeted therapies, significant challenges remain, such as the complexity of ROS dynamics, resistance mechanisms, and the influence of the tumor microenvironment. This review aims to shed light on current advancements and emphasize the need for further research to refine therapeutic strategies that leverage the ROS pathway in AML.

Indexed as

Antineoplastic AgentsBiological ProductsLeukemia, Myeloid, AcuteReactive Oxygen SpeciesAnimalsApoptosisHumansMolecular Targeted TherapyOxidative StressTumor MicroenvironmentAntineoplastic AgentsBiological ProductsReactive Oxygen SpeciesAMLCancer therapyOxidative stressROS

Identifiers

PMID40163149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.